We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
Moderate to strong cytoplasmic positivity was observed in colorectal, breast and ovarian cancer as well as a few cases of cervical, endometrial and liver cancers. Prostate cancer and several cases of pancreatic, gastric, testicular, urothelial and thyroid cancer were moderately stained. Remaining cancer cells were weakly stained or negative.
A majority of cancers displayed weak to moderate cytoplasmic positivity. Thyroid cancers and a few colorectal and prostate cancers were strongly stained.
Most cancer tissues showed moderate cytoplasmic and membranous positivity. Gliomas were weakly stained or negative.
GENE INFORMATION
Gene name
FANCL (HGNC Symbol)
Synonyms
FAAP43, FLJ10335, PHF9, Pog
Description
Fanconi anemia, complementation group L (HGNC Symbol)
Entrez gene summary
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group L. Alternative splicing results in two transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]